Malignancies occur with a higher incidence rate and manifest earlier in life in patients with primary immunodeficiency disorders (PIDs) than in the general population. However, no universal mechanism of malignancy predisposition in patients with PIDs has been determined. Despite strong support for the physiologic role of tumor immunosurveillance and the increasing success of strategies in immunologic tumor therapy, which include checkpoint inhibition, mAbs, and engineered T-cell antigen receptors, the incidence and pattern of malignancies in patients with PIDs do not reflect an increased tumor immune escape per se. In contrast, malignancies appear to be restricted to either (1) tissue types bearing the same molecular defect that underlies the PID, such as syndromes of DNA repair deficiency or immune cell-specific maturation or functional defects that suggest a cell-intrinsic oncogenic basis, or (2) other tissues when they are infected by transforming viruses or chronically inflamed, pointing toward extrinsic causes for transformation that are potentially facilitated by but not predominantly caused by a lack of immunosurveillance. Based on recent studies of pre-existing conditions in patients with malignancies and on malignancies in large PID cohorts, we conclude that a large part of tumor predisposition in patients with PIDs is derived from the same molecular defect as the immunodeficiency itself. The presented concept elucidates diverse pathomechanisms and risks of malignancies in patients with PIDs in light of current tumor immune therapies. (J Allergy Clin Immunol 2018;141:59-68.)
Key words: Primary immunodeficiency, malignancy, tumor predisposition, immune surveillance, pre-existing condition Malignancies occur more frequently and earlier in life in patients with primary immunodeficiency disorders (PIDs) than in the general population and comprise B-or T-cell lymphoma, Hodgkin lymphoma, (myelodysplastic syndromerelated) leukemia, carcinoma, and, rarely, melanoma, medulloblastoma, neuroblastoma, or other tumors. 1, 2 The recognized tumor immunosurveillance theory proposed by Burnet 3, 4 and reviewed by Dunn et al 5 has been discussed controversially but was rehabilitated as one of the emerging hallmarks of cancer early in this millennium. 6 With the increasing availability of technical tools to establish a molecular diagnosis in patients with PIDs, malignancy, or both, one might expect that it would be possible to gain more detailed insight into the pathophysiology of tumor surveillance in the context of inborn errors of the immune system. The occurrence of malignancy is considered a hallmark of primary and secondary immunodeficiencies 2 and is listed as a PID-associated feature (eg, in the PID classification of the International Union of Immunological Societies 7 ). Additionally, malignancies are described as diagnostic criteria in the database of the European Society for Immunodeficiencies (ESID) 8 and in a prospective study of profound combined immunodeficiencies (CIDs). 9 Nevertheless, the proportion of patients with PIDs among patients with malignancies is surprisingly small, and the subgroups of PIDs that are predominantly involved are few.
An array of mostly indirect pieces of evidence has been collected that corroborates the physiologic role of immunosurveillance in vivo (recently reviewed by Corthay 10 ), such as the incidence of malignancy in patients with secondary immunodeficiency disorders that include pharmacologic immunosuppression in transplant recipients or acquired immunodeficiency syndrome, immune reactions against tumor cells and tumor immune evasion mechanisms, and, last but not least, the clinical success of checkpoint inhibition through cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) blockade. 10 However, it remains unclear as to why malignancies like melanoma and renal cell carcinoma, which have historically been considered and used as proof of immunotherapy principles, are not found more frequently in patients with PIDs than in members of the immunocompetent population. Furthermore, the spectrum of malignancies in patients with PIDs appears to be restricted to a From a few oncologic entities. With rare exceptions, these are predominantly of either hematologic origin and are linked to the cell type harboring the underlying immunodeficiency, are of hematologic or epithelial origin in patients with DNA repair deficiencies, or can be explained by the co-occurrence of chronic inflammation or infection with oncogenic viruses. 1, 2 To clarify the picture of the factual association of malignancies with PIDs, a synopsis of mechanisms potentially involved in tumor predisposition in patients with PIDs is provided in this article, and most recent descriptive studies are interpreted from both the oncologic and immunodeficiency view, focusing on the correlation of malignancies with PIDs.
THE IMMUNOLOGIC AND BIOLOGICAL PERSPECTIVE: CATEGORIES OF PID-ASSOCIATED TUMOR PREDISPOSITION
Malignancies that occur in patients with PIDs can arise from 6 categories of causes that can be divided additionally into primary or intrinsic and secondary or extrinsic groups (Fig 1, I .1-3 and E.1-3, respectively, panels 1-7, and Table I ). These tumorpredisposing factors are not mutually exclusive but might add to or even depend on each other. We propose that intrinsic factors play a predominant role in those PIDs in which the malignant transformation occurs either in the same cell type that has been primarily affected by the immunodeficiency or in another cell type but on an identical molecular basis. Such categories of PIDs with intrinsic tumor predisposition are as follows: I.1, stem cell, myeloid, and lymphoid development, differentiation, and apoptosis defects; I.2, lymphocyte (co-)signaling, cytoskeleton, cytotoxicity, and metabolism defects; and I.3, defects in chromosome stability, telomere maintenance, and DNA repair (Table I , left column, and Fig 1, panels 1-4) . For example, impairments in repair of DNA double-strand breaks (DSBs) lead to severe combined immunodeficiency (SCID) through defective V(D)J recombination and can give rise to malignant lymphoma on the basis of the DNA repair defect. In categories I.1 to I.3 the risks of malignancy and immunodeficiency exist in parallel rather than in serial connection with one another. Thus the intrinsic tumor predisposition in patients with PIDs implies that any PID-dependent specific loss of tumor immunosurveillance might only be an additional modifying factor for tumorigenesis but not the primary cause. Other reasons for malignant transformation are extrinsic to the affected immune function in patients with PIDs and mainly cause malignancy in other tissues than the cell type that is primarily affected by the PIDs. Such extrinsic causes of tumor predisposition in patients with PIDs are as follows: transforming viral infection (E.1), chronic tissue inflammation (E.2), and impaired specific tumor immunosurveillance (E.3; Table I , right column, and Fig 1, panels  5-7 ). In the scenarios E.1 to E.3 the risk of malignancy arises secondarily to the PIDs because malignant transformation is either indirectly facilitated by the underlying PIDs through failure to eliminate or control oncogenic viruses or chronic inflammation or directly because of the failure to recognize and neutralize or remove transformed cells. Only the latter mechanism (E.3) represents failed immunosurveillance in the strict sense.
The distribution of the distinct types of malignancies in various categories of PIDs corroborates the proposed hypothesis of the existence of intrinsic and extrinsic causes of oncogenesis and will be explained along a gross developmental order, as depicted clockwise in Fig 1 ( starting from the top center with panel 1). For example, the risk of myeloid malignancies predominates in the first group, termed ''stem cell and myeloid developmental defects'' (Fig 1, top center panel 1) . Severe congenital neutropenias (SCNs) are classified as defects of phagocyte number, function, or both and are characterized by a stem cell and myeloid differentiation defect that leads to neutropenia and, depending on the genetic cause, to myelodysplastic syndrome and acute myelogenous leukemia (Fig 1, category I ). The genetic causes and, consequently, the pathophysiology of SCNs are variable. This implies that protein and vesicle mistrafficking, endoplasmic reticulum stress, the unfolded protein response, destabilization of the mitochondrial membrane potential, disturbed energy metabolism, dysglycosylation, and deregulated actin polymerization are taking place (reviewed by Hauck and Klein 12 ). The resulting intrinsic stem cell and myeloid development defects but not neutropenia, as such, infer tumor predisposition. Additionally, evidence exists that high-dose treatment with granulocyte colony-stimulating factor continuously overstimulates the defective system and adds to the overall risk of malignancy, at least in a subgroup of patients with SCN-causing ELANE mutations (reviewed by Makaryan et al 13 ). Mutations leading to haploinsufficiency of GATA2, a key zinc finger transcription factor of hematopoiesis, are responsible for Emberger and MonoMac syndromes. 14, 15 Patients with these syndromes display a wide spectrum of symptoms ranging from deafness, lymphedema, alveolar proteinosis, infections, B and dendritic cell hypoplasia, NK cell deficiency and monocytopenia, neutropenia, familial thrombocytopenia, and myelodysplastic syndrome or myeloid leukemia (category I.1). [14] [15] [16] [17] [18] Other bone marrow failure syndromes that stem from ribosome biogenesis defects, such as Shwachman-Bodian-Diamond syndrome (SBDS) and cartilage-hair hypoplasia (CHH) impose a tumor predisposition syndrome and, in the case of CHH, might be associated with a state of CID with variable severity (reviewed by Notarangelo et al 19 ; Fig 1, category I.1, panel 1) . SBDS is associated with exocrine pancreas insufficiency and neutropenia or pancytopenia and an increased risk of myelodysplasia and acute myelogenous leukemia. 20, 21 Again, the risk of malignancy in patients with SBDS and CHH cannot be attributed to immunosurveillance in the strict sense but rather to the intrinsic hematopoietic/myeloid cell defect based on ribosome pathology (category I.1).
The second example for an immune cell-intrinsic risk of malignant transformation comprises lymphocyte development, maturation, and apoptosis defects (Fig 1, category I .1, top right panel 2). The lymphocyte apoptosis defect in patients with FAS/FAS ligand-linked autoimmune lymphoproliferative syndrome (ALPS) impairs primarily lymphocyte differentiation, apoptosis, and senescence 22, 23 to an extent that both immune dysregulation and lymphoma predisposition arise 24 but does not cause or is not associated with diminished T-cell effector function against opportunistic infections. Immune cell-intrinsic disorders that cause (mostly hematologic) malignancies within the same cell type are grouped according to myeloid or lymphoid development; differentiation or apoptosis defects (''intrinsic''; I.1); lymphocyte (co)-signaling, cytoskeleton, cytotoxicity, and metabolism defects (I.2); or chromosome stability, telomere maintenance, and DNA repair defects (I.3). Tumor predisposition arising from factors independent from or secondary to the immunodeficiency are grouped under extrinsic oncogenic risk factors, such as transforming (viral) infections (E.1), chronic tissue inflammation with or without chronic infection and increased tissue turnover (E.2), or a loss of specific tumor immunosurveillance per se (E.3). The infographic does not reflect the level of incidence in or relative contribution of each category. AML, Acute myelogenous leukemia; DKC, dyskeratosis congenita; EV, epidermodysplasia verruciformis; IBD, inflammatory bowel disease; ICF, immunodeficiency with centromeric instability and facial anomalies; LPD, lymphoproliferative disorder; MDS, myelodysplastic syndrome; SDS, Shwachman-Diamond syndrome; SM, smooth muscle tumor; WHIM, warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis. 1 No malignancy as such but having the potential to progress to and/or requiring chemotherapy and/or HSCT.
2 ALPS caused by germline and/or somatic mutations. 3 Only SCID caused by defective nonhomologous end-joining. 4 Defects listed in I.1 and I.2 facilitate malignant transformation caused by viral species, such as EBV, HHV8, and human papillomavirus. 5 Defects listed in I.1-3 and E.1 lead to chronic inflammation and infection. 6 Defects listed in I.1-3 facilitate immune escape of cells that independently underwent malignant transformation.
Similarly, impairments in B-cell maturation, such as in the heterogeneous group of common variable immunodeficiency (CVID), primarily yield humoral immunodeficiencies that are associated with a congenital disorder of B-cell differentiation, B-cell receptor editing, and altered B-cell lifecycle. Some patients with CVID have lymphoma that is probably linked to chronically impaired lymphocyte differentiation (Fig 1, category I.1, panel 2). Furthermore, CVID can predispose to the development of other malignancies, such as adenocarcinoma, yielding a higher incidence compared with the general population. [25] [26] [27] Because epithelial tumors in patients with hypogammagobulinemia and CVID are typically located in the gut or lungs and are also seen in patients with IgA deficiency alone, 2 chronic infection might play a pathogenetic role on the grounds of IgA deficiency, and subsequent chronic inflammation might be suspected to be an additional tumor-predisposing factor (category E.2; Fig 1,  panel 5 ).
In patients with SCID, the risks of malignancy caused by cellintrinsic defects in the T-cell lifecycle cannot be separated clearly from those associated with defects in the molecular functional circuits (categories I.1-2, panel 2-3) and the extrinsic lack of T cell-mediated specific immunosurveillance (Fig 1, ), these patients die before a malignant disease evolves on the basis of their PIDs. Although a large US study on the outcome of HSCT for SCID did not report any pre-or post-HSCT cancers, 28 anecdotal reports of cancers in SCID survivors undergoing transplantation also exist, mainly human papilloma virus-associated skin cancer (A. Schulz, personal communication). It is unclear whether this is due to poor immune reconstitution after HSCT, the underlying germline gene defect, or toxicity of the HSCT itself. Recently, researchers demonstrated in vitro that mutations in RAG1 from patients with SCID or Omenn syndrome cause genotype-specific distinct DNA breaks and differentiation blocks in T-cell development 29 that might explain both the immunodeficiency phenotype and the potential lymphoma and leukemia predisposition, supporting the intrinsic oncogenesis hypothesis, at least for this molecular SCID entity.
Third, an important subgroup of CIDs deserves special attention because many of them are predisposed to Hodgkin and non-Hodgkin B-cell lymphoma, Burkitt lymphoma, and nonmalignant but nevertheless potentially fatal lymphoproliferative disorders, including hemophagocytic lymphohistiocytosis (HLH). 7, [30] [31] [32] [33] [34] [35] [36] Substantial molecular heterogeneity exists in this subgroup, and the intrinsic defects comprise lymphocyte (co)-signaling, cytoskeleton, cytotoxicity, and metabolism defects (Fig 1, category I.2, panel 3) . Functionally, the pathomechanisms result in impaired T-cell/B-cell crosstalk and effector or memory T-cell generation on encounters with EBV and other transforming (herpes) viruses.
Representative (co-)signaling defects are impairments in T-cell receptor-mediated T-cell activation (MAGT1 deficiency), CD28 cosignaling (CARMIL2 deficiency), 37 and, most prominently, the CD27-CD70 axis 30, 32, 38 and SLAM receptor family (switch)-signaling deficiencies (Purtilo syndrome, SLAM-associated protein [SAP] deficiency). 39 Purtilo syndrome is a prominent and instructive example of this category because deficiency of the intracellular adaptor molecule SAP changes the signaling outcomes of homotypic and heterotypic SLAM receptor interactions in hematopoietic cells. In particular, SAP deficiency results in an natural killer (NK) cell/B-cell and T-cell/B-cell interaction disorder that severely interferes with elimination of EBV-infected B cells and thus, after primary EBV infection, leads to EBVtriggered HLH. Next, if SAP-deficient subjects survive this initial HLH because of sufficient treatment or somatic SAP reversions that potentially occur in EBV-specific cytotoxic CD8 T cells, they are at risk of EBV-induced malignant transformation and especially can experience mucosa-associated lymphoid tissue lymphoma, again as a consequence of impaired NK cell/B-cell and T-cell/B-cell interactions. Additionally, EBV-naive subjects or survivors of primary EBV infection can have hypogammaglobulinemia as a consequence of inefficient interactions of follicular helper T cells and germinal center B cells. Thus Purtilo syndrome clearly exemplifies how a unique molecular defect leads to a particular cell-intrinsic disorder that in combination with an extrinsic factor can lead to malignancy. [40] [41] [42] Cytoskeletal defects impair the formation of the immunologic synapse and are particularly well illustrated in patients with WAS. 43 Metabolic disorders, such as cytidine triphosphate synthase 1 deficiency, suppress effector T-cell expansion and virusspecific memory T-cell differentiation. 44 If the physiologic detection of DNA DSBs fails or other DNA repair defects that lead to genetic instability are present, uncontrolled cell-cycle progression and oncogenesis occur, and at the same time, the repair of physiologically induced DSBs, such as Tcell and B-cell antigen receptor V(D)J rearrangement and classswitch recombination, is abrogated (Fig 1, category I.3, panel 4) . The impaired DNA damage response causes immunodeficiency in parallel with tumor predisposition, which is in line with the hypothesis mentioned above (Table I, Others include constitutive mismatch repair deficiency (CMMRD) and radiosensitivity disorders, such as deficiencies of DNA ligase 4 (LIG4), DNA-dependent protein kinase catalytic subunit (PRKDC), Cernunnos (NHEJ1), Artemis (DCLRE1C), and others. 7, [45] [46] [47] The association between AT and NBS and malignancies has been analyzed recently in large French and European cohorts, respectively, 48, 49 and its quantitative contribution exceeds that of all other PIDs by far. 1 Although the vast majority of malignancies are T-NHL in AT, B-non-Hodgkin lymphoma (NHL) in NBS, other lymphoma and leukemia that often involve 14q aberrations in AToccur. Additionally, other types of malignancies, such as carcinoma, that occur later in life than hematologic malignancies but much earlier than in the general population, as well as sarcoma, medulloblastoma, or neuroblastoma, were observed, especially in patients with NBS, Bloom syndrome, and CMMRD (Table II) . 1, [48] [49] [50] [51] [52] The recently reported association of profound CID, monoclonal lymphoproliferative disease, and increased chemosensitivity in a patient with familial tumor predisposition and mutated RAD52 fits this picture. 53 Until now, no malignancies have been reported in patients with radiosensitive SCID caused by mutations in PRKDC or MRE11, probably because DNA-dependent protein kinase, catalytic subunit-deficient human subjects have no T-and B-cell development at all (reviewed by de Miranda et al 47 ), and MRE11 deficiency might be partially compensated by other components of the NBN/RAD50/MRE11 complex. Given the particular requirement for DSB repair in the immune system and the overall importance in maintaining genomic stability, SCID frequently observed in these patients might be seen as a byproduct rather than the cause of the tumor predisposition. 47 Nevertheless, the relevant contribution of functional T-cell immunosurveillance was demonstrated recently in T cell-deficient Atm knockout mice that had B-cell lymphoma that was not transplantable to immunocompetent mice. 54 Prime examples of primarily extrinsic causes of oncogenic transformation are shown in Fig 1 (bottom left to top left, panels  5-7) . The chronic inflammation of epithelial surfaces or tissues or infections with oncogenic viruses might induce malignant transformation. This is known to occur more frequently in patients with PIDs or secondary immunodeficiency disorders than in members of the general population (Fig 1, categories E1-2 , panels 5-6). Epidermodysplasia verruciformis is caused by mutations in the TMC6 and TMC8 genes and, for example, predisposes patients to papillomavirus infections and skin cancer (Fig 1, category E.1,  panel 5) . 55 However, malignancy associated with chronic inflammation and infection also occurs in otherwise immunocompetent subjects (eg, hepatitis C virus and hepatocellular carcinoma, Helicobacter pylori and gastric cancer). 56, 57 Hence it might be argued whether the increased frequency of chronic tissue inflammation caused by an inability to fend off mostly viral infections in patients with PIDs alone (category E.2) or a combination with impaired cancer immunosurveillance (category E.3) leads to malignancy in this scenario. Cytotoxicity defects underlie fulminant lymphoproliferative disorders and are classified as familial hemophagocytic lymphohistiocytosis. 7, 58 As described above, they represent an overlap subgroup with respect to the basis of malignant transformation because in addition to the T cell-intrinsic defects (Fig 1, category I.2, panel 3) , strong extrinsic contributions in the form of oncogenic viral infection and impairments in specific immunosurveillance exist in this group (Fig 1, categories E. 1 and E.3, panels 5 and 7).
Lastly, NK cells are known to play a major and undoubted role in tumor immunosurveillance, as do other components of the innate immune system, such as dendritic cells, cytokines, and intracellular and extracellular receptors. 5 It is surprising that, apart from disorders of cytotoxic granule formation or their secretion and NK and T-cell cytotoxicity defects, resulting in primary HLH, 59 patients with congenital defects in NK cell numbers or function do not have an increased risk of developing cancers in the context of impaired immunosurveillance. 60 A comprehensive list of primary immunodeficiencies with reported or expected malignancy, the causal genes, mode of inheritance, and references is provided in Table E1 in this article's Online Repository at www.jacionline.org.
THE ONCOLOGIC PERSPECTIVE: TYPES AND CHARACTERISTICS OF MALIGNANCIES OBSERVED IN PATIENTS WITH PIDs
Two large retrospective registry studies were published on AT and NBS in 2015, 48, 49 and the main patients' characteristics and conclusions are presented in Table II . Although the AT study focused on malignancies in a national cohort and was more detailed with regard to histologic subtypes of malignancies and treatments, 49 the NBS study was performed Europe-wide as a retrospective ESID survey and provided an overview of the most relevant clinical presentations and complications of patients with NBS. 48 The results of both studies reflected previous knowledge because the incidence of lymphoma was much greater in both DNA repair defects/immunodeficiencies as in the general population and as in patients with other PIDs. The proportion of T-prolymphocytic leukemia in patients with AT was smaller than had been expected in the French cohort on the basis of previous studies. 49 Malignancy was the strongest negative factor affecting survival in both patients with AT and those with NBS. 48, 49 Although toxicity has been a serious concern in the treatment of malignancy in patients with DNA repair deficiencies who are radiosensitive, chemosensitive, or both, 61, 62 HSCT has been performed relatively successfully in patients with NBS and was proposed for patients in first remission, 48, 63 given its potential to replace the tissue that is prone to future primary and secondary malignant transformation. Recently, a large retrospective multicenter study was conducted to evaluate the feasibility and outcome of HSCT in DNA repair defects, with 29 transplantations indicated for immunodeficiency-related infections, 21 for malignancy, 13 for bone marrow failure, 13 for pre-emptive reasons, and 11 for unknown or multiple reasons. 64 The cohort of 87 patients included NBS, LIG4 deficiency, Cernunnos deficiency, and AT, with a survival of 69%. 64 Deaths mostly occurred early after HSCT and significantly more frequently in patients who had been treated with myeloablative conditioning compared with those started on reduced-intensity regimens, which correlated with increasingly toxic effects in these patients. 64 Patients with AT had the poorest outcome with only 25% survival, leading to the conclusion that HSCT should not be routinely recommended in patients with AT. 64 No secondary malignancies were observed in this cohort during the relatively short median follow-up period of 35 months. 64 In addition, at least 4 recent studies have been conducted to investigate the more general associations between malignancy and PID. First, a Dutch national survey of patients with PIDs in the ESID registry was conducted to analyze the incidence and type of malignancy. 50 This study included patients of all age groups and showed that the most prevalent subcategory of PID, namely predominant antibody deficiency, was associated with the highest number of malignancies, mostly squamous cell carcinoma of the skin, with a 2.3-fold higher risk than in the general population. When the lymphoma incidence was calculated, the risk in patients with PIDs from The Netherlands was increased 11-fold, and again, these cases were derived mainly from the largest group of PIDs, namely patients with hypogammaglobulinemia and CVID.
Second, as a result of a database search using the key phrases ''childhood cancer'' and ''genetic syndrome/disorder'' for relevant literature from the past 50 years, 1 PID-linked syndromes were found to be accountable for only a minority of malignancies in overall pediatric oncology compared with other well-known tumor predisposition syndromes, such as Li-Fraumeni, Noonan, Beckwith-Wiedemann, and Down syndromes as well as neurofibromatosis and familial adenomatous polyposis coli. However, many hematologic malignancies were found in patients with syndromes known to cause PIDs (Table II) . 1 The preliminary results of an ongoing study in Austria indicate that similar conclusions can be reached (Table II; Voss and Seidel, unpublished  data) .
Third, a multicenter study on NHL linked to pre-existing conditions in children and adolescents conducted by the European Intergroup for Childhood NHL and the International BerlinFrankfurt-M€ unster study group led to the identification of 213 patients with PIDs for whom AT (n 5 32) and NBS (n 5 26), followed by CMMRD (n 5 21), unspecified PID (n 5 21), SAP deficiency (n 5 11), WAS (n 5 7), and CVID (n 5 8), made up the majority of syndromic NHL. Other PIDs included ALPS, CHH, serine/threonine kinas 4 deficiency, hyper-IgM syndrome, and hyper-IgE syndrome (each n 5 2) and other non-PID tumor predisposition syndromes (Table II) . 51 A similar study on acute lymphoblastic leukemia (ALL) was conducted within the European AIEOP-BFM ALL 2000 trial group and led to the identification of 233 patients of 4939 children and adolescents given a diagnosis of ALL between 1999 and 2009 who had a preexisting condition. 52 Among those that were detected more often than once, AT (n 5 8) and NBS (n 5 6) were the only PIDs, whereas other diagnoses included Gilbert disease, neurofibromatosis, thalassemia, and Noonan and Klinefelter syndromes. 52 The directors of both studies concluded that patients with ALL and pre-existing conditions required adjustments in chemotherapy and intensified supportive care.
CONCLUSIONS AND PERSPECTIVES
These observations of the types of malignancies and their frequent manifestations in defined pathophysiologic PID subtypes raise the following questions and allow us to reach several conclusions.
First, why is the malignant cell lineage in a PID-associated malignancy often identical to the cell type affected by the immunodeficiency, or why is the malignancy attributable to the same underlying molecular defect rather than attributable merely to a defect in tumor antigen presentation or recognition? Why are melanoma, renal cell carcinoma, and non-small cell lung cancer relatively rare in patients with PIDs, although they are tumors NA (100% AT) B-NHL, HD, ALL in childhood and adolescence; from young adulthood also PLL and carcinoma
More increased incidence of lymphoma and leukemia than in general population; patients with AT and cancer have shorter survival than those without.
Immunodeficiency (immunoglobulin substitution, IgA and B-cell deficiency) associated with higher cancer incidence; type of ATM mutation not linked to risk of malignancy NA (100% NBS) B-NHL, T-NHL, T-ALL, HD, other malignoma including medulloblastoma, neuroblastoma
More increased incidence of lymphoma and leukemia than in general population; NBS patients with cancer have shorter survival than those without.
HSCT feasible (n 5 14 patients, all because of relapse of malignoma, of whom 9 survived 1.4-11 y); no predictive clinical or laboratory biomarker for cancer development detectable
Predominant antibody deficiency
Forty solid tumors (mainly squamous cell carcinomas of the skin), lymphoma, leukemia
Risk of any malignancy is 2.3-fold higher in patients with PIDs than in general population; that of lymphoma was 11-fold greater.
Cancer occurs earlier and with increased frequency in patients with PIDs than in the general population; lymphoma showed male predominance NBS (also het. NBN mutations), GATA2, AT, SCN, Bloom
Leukemias, NHL, HD; rarely also medulloblastoma, others
Leukemia and lymphoma are most prevalent cancer in patients with PIDs.
Minority of cancer predisposition syndromes is associated with or categorized as immunodeficiency.
AT ( In line with these questions is the observation that in the human diseaseome (ie, a network of human disorders, disease genes, and their respective gene-product interactions) PIDs do not cluster with malignancy, with a few exceptions, such as NBS, AT, and ALPS-related autoimmune diseases. 65 Importantly, Fanconi anemia (FA) lies near the center of the diseasome malignancy cluster close to TP53 and PTEN 65 and has been associated with an increased risk of bone marrow failure with leukemic transformation in childhood or adolescence and of ear-nose-throat and other carcinomas early in adulthood without being associated typically with clinically relevant immunodeficiency. 66 Because FA is based on a comparable DNA repair deficiency, such as AT and NBS, but does not disrupt immunoglobulin production or induced detectable T-cell dysfunction, FA causes a similar tumor predisposition as AT or NBS without any major loss of immunosurveillance. 67 In addition, the fact that DBA causes a predisposition toward malignancies comparable with CHH and SBDS (eg, myelodysplastic syndrome and myeloblastic leukemia but rarely lymphoma or osteosarcoma) without being associated with immunodeficiency indicates that immunosurveillance does not substantially contribute to these malignancies. 1, 68, 69 In conclusion, we argue that particularly genomic instability, as well as defects in DNA repair and ribosome biogenesis, strongly favor oncogenesis and that impaired immunosurveillance might represent an additional but probably minor risk factor in patients with PIDs with a strong intrinsic tumor predisposition (I.1-3).
Second, given the success of combined checkpoint inhibition in the current treatment of malignant melanoma, non-small cell lung cancer, and other malignancies investigated in clinical trials (reviewed by Pardoll 70 ), one would expect to find a reduced tumor predisposition in patients with inborn loss-of-function defects in PD1, its ligands, or other inhibitory immune checkpoint modifiers, whereas those subjects would be expected to have autoimmunity and immune dysregulation. Presumably, a reduced risk of malignancy might be impossible to identify in clinical epidemiologic practice. To date, inborn PD1/programmed death ligand 1 defects with autoimmunity have been identified in mice 71 but have not been found in human subjects, and gain-offunction mutations with increased tumor predisposition are currently unknown. On the contrary, patients with haploinsufficiency of CTLA4 have autoimmunity but, at the same time, are not entirely protected from malignancies, such as lymphoproliferation, lymphoma, or gastric cancer. [72] [73] [74] [75] [76] Tumor immune surveillance and protection from autoimmunity can be seen as 2 sides of a coin named ''tolerance.'' Thus autoimmune phenomena occur in oncologic patients treated with checkpoint inhibition (see comment in Lo et al 77 ), and consequently, one might suspect that tumors will arise in patients undergoing long-term abatacept or belatacept treatment, such as patients with rheumatoid arthritis, organ transplant recipients, or patients who are CTLA4 or LRBA deficient. 78 It has been shown that a positive response to immune checkpoint inhibition correlates with the mutational load of a tumor, 79, 80 which is expected to be greater in tumors with genomic instability, such as CMMRD, or potentially other repair defects. This suggests that more tumor-associated, mutation-derived neoantigens might be identified and targeted by the immune system in patients with such malignancies. 79, 80 In fact, patients with DNA mismatch repair-deficient colorectal cancers responded substantially better to a PD1 blockade than patients with DNA mismatch repair-proficient cancers, as shown by an immune-related, progression-free survival rate of 78% versus 11%, respectively. 81 Whether the same will hold true for germline CMMRD mutations or other DNA repair defects, the predominant group of cancer-predisposing PIDs is currently unknown. In this case tumors could show a higher mutational burden, but simultaneously, patients have a variable degree of CID and therefore might have an inefficient antitumor immunity, even if enhanced by pharmacologic checkpoint inhibition. By conducting a critical review of the specific pattern of actual tumor predisposition of patients with PIDs, we might optimistically hypothesize that checkpoint inhibition could serve as an extremely helpful addition to conventional oncologic therapy, especially in these highly radiosensitive and chemosensitive patients. At the same time, the success of that strategy would be the prime piece of evidence that would weigh against the predominant role of lost tumor immunosurveillance as the cause of cancer in patients with PIDs. On the contrary, if patients with checkpoint inhibition therapy exhibited poorer responses after having PID-related cancers despite programmed death ligand 1 expression than otherwise healthy subjects with the same types of malignancies, this might provide support for the argument that patients must possess the respective immune mechanism to eradicate tumor cells.
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